Mozart Ther­a­peu­tics se­cures $25M ex­pan­sion to Se­ries A; Lian­Bio un­veils PhI­Ia da­ta for gas­tric can­cer treat­ment

Mozart Ther­a­peu­tics, a Seat­tle-based biotech cen­tered on de­vel­op­ing CD8 treg mod­u­la­tors to treat au­toim­mune and in­flam­ma­to­ry dis­eases, has raised $25 mil­lion from new in­vestors to ex­tend its Se­ries A. Mozart’s ex­ist­ing in­vestors in­clude Sofinno­va Part­ners, Eli Lil­ly & Com­pa­ny, ARCH Ven­ture Part­ners, Mer­ck’s MRL Ven­tures Fund, Leaps by Bay­er, Al­ti­tude Life Sci­ence Ven­tures and Alexan­dria Ven­ture In­vest­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.